

(10) International Publication Number
WO 2016/196346 A1(43) International Publication Date
8 December 2016 (08.12.2016)

(51) International Patent Classification:

A61K 31/4439 (2006.01) C07D 317/06 (2006.01)
C07D 317/02 (2006.01) C07D 487/04 (2006.01)

(21) International Application Number:

PCT/US2016/034782

(22) International Filing Date:

27 May 2016 (27.05.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/168,529 29 May 2015 (29.05.2015) US
62/168,581 29 May 2015 (29.05.2015) US
62/269,745 18 December 2015 (18.12.2015) US

(71) Applicant: EISAI R&D MANAGEMENT CO., LTD.
[JP/JP]; 6-10, Koishikawa 4-Chome, Bunkyo-ku, Tokyo,
112-8088 (JP).

(72) Inventors: BOCK, Mark; 285 Columbus Avenue, #704,
Boston, Massachusetts 02116-5296 (US). HAO, Ming-
Hong; 138 Quincy Shore Drive, #173, Quincy, Massachu-
setts 02171 (US). KorpAL, Manav; 18 Myrtle Street,
Winchester, Massachusetts 01890 (US). NYAVANANDI,
Vijay Kumar; H. No. 1-1/40, Krishna Sai Enclave, HMT
Colony Road, Miyapur, Hyderabad, Andhra Pradesh
500049 (IN). PUYANG, Xiaoling; c/o H3 Biomedicine
Inc., 300 Technology Square, Cambridge, Massachusetts
02139 (US). SAMAJDAR, Susanta; Flat No. R801, HM
Tambourine, JP Nagar 6th Phase, Bangalore, Kamataka
560078 (IN). SMITH, Peter Gerard; 173A Franklin
Street, Arlington, Massachusetts 02474 (US). WANG,

John; 2 Governor's Drive, Andover, Massachusetts 01810
(US). ZHENG, Guo Zhu; 14 Meriam Street, Lexington,
Massachusetts 02420 (US). ZHU, Ping; 44 Coolidge Farm
Road, Boxborough, Massachusetts 01719 (US).

(74) Agents: WALTERS, Todd R. et al.; Buchanan Ingersoll
& Rooney PC, P. O. Box 1404, Alexandria, Virginia
22313-1404 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE

FIG. 3



(57) Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER- α protein.